Facility expansions and new line start-ups are often seen as positive milestones for pharmaceutical companies. They may signal growth, increased capacity, new product introductions, improved technology or a stronger market position. However, from a Quality Assurance perspective, they also represent periods of heightened risk. When a new manufacturing area, packaging line, laboratory, warehouse space,
The pharmaceutical factory is changing. For decades, quality decisions were often made after the event: after a batch record was reviewed, after laboratory results were returned, after a deviation was raised, or after a trend was identified during periodic review. Today, the growth of connected manufacturing systems, automated process controls, electronic batch records, manufacturing
In pharmaceutical manufacturing, raw materials are often discussed as inputs. In reality, they are far more than that. They are one of the foundations of product quality, process consistency, regulatory compliance and patient safety. As global supply chains become more complex, and as pharmaceutical companies face greater pressure around resilience, cost, continuity of supply
Sustainability is no longer a peripheral conversation in pharmaceutical packaging. It is becoming a strategic, regulatory and operational priority for pharmaceutical companies, contract manufacturers, packaging suppliers and marketing authorisation holders. Across Europe and the UK, organisations are under increasing pressure to reduce packaging waste, improve recyclability, use materials more efficiently and demonstrate responsible environmental
In pharmaceutical manufacturing, the terms Quality Assurance and Quality Control are often used together, and sometimes incorrectly used interchangeably. Both are essential to product quality, GMP compliance and patient safety, but they are not the same function. For QA and QC professionals, understanding the difference matters. It shapes responsibilities, career pathways, team structures, inspection
Advanced therapies are changing what is possible in medicine. Cell therapies, gene therapies and tissue-engineered products are creating new opportunities for patients with serious, rare and complex diseases. However, they also bring manufacturing, testing and quality challenges that are very different from traditional pharmaceutical products. For QA and QC teams, this creates a critical
Cell therapy manufacturing is one of the most exciting and demanding areas in life sciences. It sits at the intersection of advanced biology, personalised medicine, complex supply chains and highly controlled GMP operations. For QA and QC teams, the challenge is clear: how do we scale cell therapy manufacturing without losing the quality control
For quality assurance professionals, sustainability can sometimes feel like a difficult conversation. On one side, organisations are under growing pressure to reduce waste, lower energy consumption, cut carbon emissions and improve environmental performance. On the other hand, GMP environments are built on control, consistency, validation, documentation and patient safety. So, can sustainability and GMP
Temperature-sensitive products leave very little room for complacency. Whether the product is a vaccine, biologic, cell therapy, diagnostic reagent, clinical trial material or pharmaceutical product requiring controlled storage, the cold chain is only as strong as its weakest handover. For QA teams, this means quality oversight can no longer stop at the warehouse door.
In pharmaceutical manufacturing, batch release is one of the most critical stages in the product lifecycle. Delays at this stage can create significant operational, financial, and supply chain challenges, impacting everything from inventory levels and production schedules to patient access and regulatory compliance. For modern Quality Assurance (QA) teams, reducing batch release delays has
